Skip to main content

Table 1 Baseline characteristics of patients who initiated treatment with saxagliptin or sitagliptin

From: Comparison of charges and resource use associated with saxagliptin and sitagliptin

  Before propensity matching After propensity matching
Saxagliptin (n = 8438) Sitagliptin (n = 23,155) P value Saxagliptin (n = 7711) Sitagliptin (n = 7711) P value
Demographics
 Age, years, mean (SD) 54.4 (10.0) 54.8 (10.6) 0.001 54.53 (9.96) 54.58 (10.60) 0.7590
 Men, % 56.6 55.9 0.265 56.28 56.63 0.6610
 Index year, %    <0.001    0.0132
 2010 43.0 54.8   45.13 39.49
 2011 57.0 45.2   54.87 60.51
Comorbidities, %
 Cardiovascular disease 20.3 21.2 0.067 20.50 19.98 0.4228
 Obesity 10.5 11.1 0.194 10.58 10.47 0.8133
 Dyslipidemia 71.9 67.7 <0.001 71.40 72.45 0.1466
 Stroke 2.9 3.3 0.126 3.00 3.00 1.000
 Atherosclerosis 1.9 2.1 0.337 1.92 1.74 0.4001
 Retinopathy 4.3 4.6 0.189 4.45 4.38 0.8446
 Hypertension 69.7 66.1 <0.001 68.88 70.35 0.0459
 Nephropathy 2.5 2.7 0.305 2.48 2.54 0.7969
 Diabetic foot problems 0 0 0.432 0.03 0.03 1.000
 Neurological complications 5.5 5.4 0.763 5.38 5.45 0.8588
 Dental disease 0.1 0.1 0.754 0.08 0.06 0.7629
 Renal impairment 6.9 7.3 0.315 6.87 6.94 0.8738
 Psychiatry diagnostic group 11.0 11.6 0.147 11.18 10.43 0.1324
 DCSI 1–4 27.4 27.1 0.624 27.45 26.91 0.624
 DCSI ≥5 4.7 5.5 0.002 4.72 4.67 0.8790
 CCI, mean (SD) 1.66 (1.35) 1.69 (1.49) <0.05 1.66 (1.35) 1.67 (1.40) 0.8292
Baseline resource use
 Copay value for index drug at index date, mean (SD) 55.3 (34.4) 35.9 (27.4) <0.001 52.57 (32.64) 50.39 (33.88) <0.0001
 Baseline overall charges (%)    <0.001    0.7638
 Quartile 1 (lowest charges) 17.7 19.2   17.66 16.95  
 Quartile 2 28.2 26.4   28.10 28.69  
 Quartile 3 30.4 28.3   30.14 30.93  
 Quartile 4 (highest charges) 23.7 26.1   24.10 23.43  
Inpatient Hospitalizations, %
 All 6.7 9.5 <0.001 7.15 6.42 0.0729
 Diabetes related 4.6 6.8 <0.001 4.86 4.50 0.4785
Baseline Pharmacotherapy
 Antidiabetic medications, % yes 75.9 72.1 <0.001 75.70 77.46 0.0097
 Antidiabetic medication classes, mean (SD) 1.32 (1.04) 1.23 (1.03) <0.001 1.31 (1.04) 1.34 (1.02) 0.0476
Polytherapy, %
 Any Polytherapy 56.3 60.8 <0.001 56.45 55.48 0.2238
 Biguanides 48.4 53.5 <0.001 48.74 46.12 0.0011
 Sulphonylureas 12.5 11.3 0.006 12.27 13.18 0.0907
 Insulin 4.2 4.2 0.949 4.16 4.44 0.4045
Other Medications, %
 Antihypertensives 68.3 66.8 0.014 67.95 68.64 0.3590
 Statins 49.3 47.5 0.005 49.02 50.12 0.1710